Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells.

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Autologous chimeric antigen receptor (CAR) T-cell therapy shows promise in cancer treatment but faces manufacturing challenges and T-cell dysfunction.
• The immunosuppressive tumor microenvironment can impede autologous CAR-T efficacy.
• Allogeneic CAR-T therapy presents a potential solution to these limitations.

Purpose of the Study:

• To review advances in generating immune cells from pluripotent stem cells (PSCs).
• To discuss the potential and perspectives of CAR-T, CAR-macrophages, and CAR-natural killer (NK) cells derived from PSCs for cancer therapy.
• To highlight the development of next-generation cancer immunotherapies by combining PSC-derived immune cells and CAR engineering.

Main Methods:

• Review of current literature on PSC differentiation into immune cells.
• Analysis of CAR engineering strategies for PSC-derived immune cells.
• Evaluation of the therapeutic potential of CAR-T, CAR-macrophages, and CAR-NK cells in preclinical and clinical settings.

Main Results:

• Pluripotent stem cells (PSCs) can be differentiated into various immune cell types, including T cells, macrophages, and NK cells.
• CAR engineering of PSC-derived immune cells enables targeted anti-cancer activity.
• Allogeneic CAR-immune cells derived from PSCs offer a standardized, "off-the-shelf" therapeutic approach.

Conclusions:

• The generation of immune cells from PSCs simplifies manufacturing and standardizes CAR-T products, addressing limitations of autologous therapies.
• PSC-derived CAR-immune cells, including CAR-T, CAR-macrophages, and CAR-NK cells, hold significant potential for advancing cancer immunotherapy.
• Combining PSC technology with CAR engineering is crucial for developing next-generation cancer treatments.